CVC Nears Final Agreement to Acquire EQT’s Ginko China Unit in Major Private Equity Handover

CVC Capital Partners Moves Closer to Finalizing Ginko China Buyout

CVC Capital Partners has advanced to final, late-stage negotiations to acquire the mainland China business of major contact lens manufacturer Ginko International, which is currently owned by European private equity firm EQT. According to sources close to the transaction, the discussions place the valuation of the prized asset in the range of $700 million to $800 million, inclusive of debt.

This development signifies a crucial step forward for a sale process that has seen significant twists over the past year. EQT originally inherited the asset following its 2022 integration with Baring Private Equity Asia. After a prior multi-billion dollar agreement with Advent International famously unraveled, EQT successfully resurrected the auction, drawing intense interest from top-tier global sponsors including Primavera Capital and Warburg Pincus before CVC emerged as the leading contender.

Strategic Rationale and Market Dynamics

The acquisition of Ginko China—renowned for prominent consumer brands like Hydron and Horien—serves as a testament to the enduring appeal of resilient healthcare and consumer staples sectors in the Asia-Pacific region. Despite macro headwinds and varying valuations across Asian capital markets, domestic consumption trends for vision care remain robust, driven by an expanding middle class and increased healthcare spending.

However, the shifting valuation landscape is worth noting. While initial market expectations and prior sale attempts targeted valuations north of $1 billion, current negotiations reflect a more disciplined pricing environment matching macroeconomic realities and risk adjustments for cross-border assets in mainland China.

• Asset Profile: Ginko China boasts extensive manufacturing and distribution infrastructure, positioning it as a dominant player in the region's optical market.
• Financial Footprint: The business demonstrated stable profitability, recording solid EBITDA figures that continue to attract premier private equity sponsors.
• Sponsor Strategy: For CVC, this potential acquisition underscores its long-standing commitment to deploying pan-regional strategies focusing on control and co-control positions in high-growth consumer segments.

Broader Implications for Cross-Border M&A

The progression of the Ginko China sale offers essential signals for institutional investors and alternative asset managers navigating the current climate. Exit routes via traditional IPO channels in domestic and regional exchanges often encounter regulatory complexities, making secondary private equity buyouts and sponsor-to-sponsor transactions the preferred mechanism for liquidity.

If CVC successfully closes the transaction, it will reinforce confidence that large-scale, high-quality consumer healthcare assets can still command deep institutional backing, provided valuations adjust to current yield expectations and risk parameters.

Key Indicators for Investors to Watch

As the transaction moves through its final phases, market participants should monitor several critical factors:

Definitive Agreement and Closing Timeline: Confirmation of signed binding contracts and regulatory clearance timelines within mainland China.

Debt Financing Structures: Given that the transaction value accounts for debt packages, tracking how the deal is syndicated will shed light on current leverage conditions in Asian credit markets.

Post-Acquisition Growth Strategy: Execution pathways implemented by CVC to drive expansion across Ginko’s manufacturing footprint and digital retail channels.